4.1 Article

Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators

期刊

CONTRAST MEDIA & MOLECULAR IMAGING
卷 7, 期 2, 页码 254-264

出版社

WILEY-HINDAWI
DOI: 10.1002/cmmi.491

关键词

HER2; Lutetium-177; nanobody; breast cancer; bifunctional chelator

资金

  1. SCK.CEN/VUB
  2. Vlaamse Liga Tegen Kanker
  3. Interuniversity Attraction Poles Program, Belgian State, Belgian Science Policy
  4. Nationaal Kankerplan Action [29]
  5. FWO-Vlaanderen [G.013910]

向作者/读者索取更多资源

Nanobodies show favourable pharmacokinetic characteristics for tumor targeting, including high tumor-to-background-ratios. Labelled with a therapeutic radionuclide, nanobodies could be used as an adjuvant treatment option for HER2-overexpressing minimal residual disease. The therapeutic radionuclide Lutetium-177 is linked to the nanobody using a bifunctional chelator. The choice of the bifunctional chelator could affect the in vivo behaviour of the radiolabeled nanobody. Consequently, we compared four different bifunctional chelators - p-SCN-Bn-DOTA, DOTA-NHS-ester, CHX-A-DTPA or 1B4M-DTPA - in order to select the optimal chemical link between Lutetium-177 and a HER2 targeting nanobody.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据